<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 2075 from Anon (session_user_id: aa05b965f90a8d76e38487fa95762b838bf82b39)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 2075 from Anon (session_user_id: aa05b965f90a8d76e38487fa95762b838bf82b39)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><p class="s4"><span><span class="s3">DNA methylation is a major epigenetic modification that is strongly involved in the physiological control of genome expression</span><span class="s3"> and</span><span class="s3"> can almost exclusively happen only on cytosines preceding guanine (CpG) in the DNA sequence</span><span class="s3">.</span></span></p>
<p class="s4"><span><span class="s3">In mammalian genomes there are </span><span class="s3">genomi</span><span class="s3">c regions that contain a high frequency of CpG sites </span><span class="s3">and are</span><span class="s3">called CpG islands</span><span class="s3">.  CpG islands</span><span class="s3"> frequently contain gene promoters or exons.</span></span></p>
<p class="s4"><span><span class="s3">Though the majority of CpG sites in human DNA are methylated, </span><span class="s3">CpG islands</span><span class="s3"> </span><span class="s3">are typically unmethylated.  </span><span class="s3">However, in cancer cells, </span><span class="s3">focal hypermethylation of promoter-associated </span><span class="s3">CpG islands are frequently seen.</span><span class="s3">  Though most of these alterations in cancers are thought to be harmless</span><span class="s3">, </span><span class="s3">cells </span><span class="s3">in </span><span class="s3">which</span><span class="s3">the tumor-suppressor genes</span><span class="s3"> </span><span class="s3">are silenced </span><span class="s3">may </span><span class="s3">have a survival advantage over normal cells and </span><span class="s3">contribute to the development of cancer.</span></span></p>
<p class="s4"><span><span class="s3">On the other hand </span><span class="s3">intergenic regions and repetitive elements are usually densely methylated</span><span class="s3"> </span><span class="s3">in normal cells</span><span class="s3"> and it helps to maintain </span><span class="s3">genomic</span><span class="s3"> stability.</span></span></p>
<p class="s4"><span><span class="s3">H</span><span class="s3">owever, the </span><span class="s3">hypo</span><span class="s3">methylation</span><span class="s3"> in those regions is frequently found</span><span class="s3"> in cancer cells</span><span class="s3"> and leads to genomic instability, such as illegitimate recombination between repeats, activation of repeats, or activation of cryptic promoters and disuruption to neighbouring genes.  G</span><span class="s3">enetic </span><span class="s3">instability causes genomic abnormality, </span><span class="s3">such as translocation, deletion, and insertion, which </span><span class="s3">contributes to </span><span class="s3">the development of cancer.</span></span></p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><p class="s4"><span><span class="s3">About 70% of Wilms</span><span class="s3">’</span><span class="s3"> tumor</span><span class="s3"> cases</span><span class="s3"> were found to have </span><span class="s3">an </span><span class="s3">overexpression of insulin-like growth factor 2 (IGF2) and inactivation of H19 was also </span><span class="s3">reported </span><span class="s3">in a number of cases.</span></span></p>
<p class="s4"><span><span class="s3">Since IGF2 is a fetal growth factor gene with an important role in cancer development and H19 is a maternally expressed non-coding RNA with possible tumor suppressor effect, </span><span class="s3">over-</span><span class="s3">expression of IGF2 and </span><span class="s3">silencing</span><span class="s3"> </span><span class="s3">of H19 can cause the development</span><span class="s3"> of cancer</span><span class="s3">.</span><span class="s3"> </span><span class="s3">The expression of the insulin-like growth factor 2 (IGF2) and H19 gene</span><span class="s3">s is</span><span class="s3"> </span><span class="s3">reciprocally </span><span class="s3">controlled</span><span class="s3"> by genomic imprinting</span><span class="s3">.</span><span class="s3">  </span><span class="s3">The Imprinting Center 1 (IC1) of IGF2, which</span><span class="s3"> is a methylation-sensitive chromatin insulator</span><span class="s3">, is</span><span class="s3"> </span><span class="s3">located between IGF2 and H19.</span></span></p>
<p class="s4"><span><span class="s3">On the paternal allele</span><span class="s3"> </span><span class="s3">the</span><span class="s3"> DNA methylation of IC1 prevents </span><span class="s3">the binding with </span><span class="s3">the multi-zinc-finger protein</span><span class="s3">CTCF and allows the enhancer-mediated activation of IGF2</span><span class="s3">,</span><span class="s3"> whereas the H19 promoter is</span><span class="s3">hypermethylated and silenced. </span><span class="s3">However,</span><span class="s3"> since IC1 on</span><span class="s3"> the</span><span class="s3"> maternal allele is not methylated,</span><span class="s3"> </span><span class="s3">it </span><span class="s3">bind</span><span class="s3">s</span><span class="s3"> with CTCF and t</span><span class="s3">his binding prevents the activation of the IGF2 promoter</span><span class="s3"> but activates the H19.</span><span class="s3">  </span></span></p>
<p class="s4"><span><span class="s3">T</span><span class="s3">he disruption of </span><span class="s3">the </span><span class="s3">H19/IGF2 cluster, such as uniparental paternal disomy</span><span class="s3"> (UPD) can cause overexpression of I</span><span class="s3">GF2 and inactivation of H19 and </span><span class="s3">lead to the development of Wilms</span><span class="s3">’</span><span class="s3"> tumor.</span></span></p></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><p class="s4"><span><span class="s3">5-AZA -2</span><span class="s3">’</span><span class="s3">-deoxycytidine (decitabine) was first synthesized in 1964</span><span class="s3">.</span><span class="s3">  </span><span class="s3">At first decitabine was </span><span class="s3">known as </span><span class="s3">a</span><span class="s3">n</span><span class="s3">antileukemic agent</span><span class="s3"> more potent </span><span class="s3">than cytosine arabinoside</span><span class="s3"> but in 1979 the unique capacity of this drug </span><span class="s3">as an</span><span class="s3"> inhibitor of DNA methylation </span><span class="s3">was discovered</span><span class="s3">.  </span><span class="s3">Though its </span><span class="s3">approval</span><span class="s3"> for the treatment of cancer took a long time</span><span class="s3">,</span><span class="s3"> </span><span class="s3">in 2006 </span><span class="s3">it was</span><span class="s3"> approved for the treatment of Myelodysplastic Syndrome (MDS)</span><span class="s3">.</span></span></p>
<p class="s4"><span><span class="s3">Decitabine is activated by phosphorylation and is incorporated into DNA by DNA polymerase.  The formation of a covalent complex between decitabine and DNMT1 at CpG methylation sites results in the inactivation of DNMT1.  DNMT1 inhibition results in DNA hypomethylation.  Since </span><span class="s3">a </span><span class="s3">variety of tumor</span><span class="s3">suppressor</span><span class="s3"> genes are inactivated by promoter methylation in tumor cells, </span><span class="s3">DNA hypomethylation res</span><span class="s3">u</span><span class="s3">lts </span><span class="s3">in</span><span class="s3">the re</span><span class="s3">activation </span><span class="s3">of the silenced tumor suppressor gene and </span><span class="s3">restoration</span><span class="s3"> of the gene function, which</span><span class="s3"> </span><span class="s3">induces</span><span class="s3">cellular differentiation, senescene and apoptosis.</span></span></p></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><p class="s4"><span><span class="s3">S</span><span class="s3">i</span><span class="s3">nce </span><span class="s3">DNA methylation is passed on during cell division to daughter cells until </span><span class="s3">it is </span><span class="s3">actively erased</span><span class="s3"> and doesn</span><span class="s3">’</span><span class="s3">t return once erased</span><span class="s3">, </span><span class="s3">if DNA methylation is </span><span class="s3">altered</span><span class="s3"> by drugs,</span><span class="s3"> </span><span class="s3">it </span><span class="s3">may</span><span class="s3"> cause</span><span class="s3"> </span><span class="s3">a </span><span class="s3">life-long </span><span class="s3">effect</span><span class="s3">.</span><span class="s3">  The d</span><span class="s3">emeth</span><span class="s3">y</span><span class="s3">lation drug </span><span class="s3">may also reduce</span><span class="s3"> the level of </span><span class="s3">DNMT1</span><span class="s3"> which</span><span class="s3"> recognizes hem</span><span class="s3">i-methylated DNA and causes</span><span class="s3"> the methylation of the non-methylated strand</span><span class="s3">,</span><span class="s3"> and </span><span class="s3">also the </span><span class="s3">reduction of DNMT1</span><span class="s3"> </span><span class="s3">may result</span><span class="s3"> in a passive demethylation</span><span class="s3"> process</span><span class="s3"> during cell </span><span class="s3">proliferation</span><span class="s3"> for a long time</span><span class="s3">.</span></span></p>
<p class="s4"><span><span class="s3">It is known that in </span><span class="s3">human </span><span class="s3">development there are times when environmental factors have a large impact on the body through epigenetic mechanisms and </span><span class="s3">they are </span><span class="s3">called sensitive periods.</span></span></p>
<p class="s4"><span><span class="s3">From the epidemiological studies, peri-conceptional period, which is during embryogenesis and gametogenesis, and slow growth period (9-12 years in grandfathers, 8-10 years in grandmother, </span><span class="s3">and</span><span class="s3">fetal/infant life for grandmothers) are </span><span class="s3">thought to be </span><span class="s3">sensitive periods.</span></span></p>
<p class="s4"><span><span class="s3">If the </span><span class="s3">DNA </span><span class="s3">methylation is altered in the</span><span class="s3">se</span><span class="s3"> sensitive period</span><span class="s3">s</span><span class="s3">, it may cause</span><span class="s3"> a variety of abnormalities</span><span class="s3"> in the patients</span><span class="s3">,</span><span class="s3"> children</span><span class="s3">,</span><span class="s3"> or grandchildren.  In light of that, we should avoid </span><span class="s3">the use of </span><span class="s3">epigenetic drugs during that period.</span></span></p></div>
  </body>
</html>